Fortress Biotech, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
Fortress Biotech, Inc. (FBIO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of $6.42 million for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-04-09.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2021-04-09
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2018-12-31 was -$2.78M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2018-09-30 was $565.00K, a 24.87% decline year-over-year.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2018-06-30 was $707.00K, a 350.32% increase year-over-year.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2018-03-31 was $118.00K.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2020 was $6.42M, a 42.43% decline from fiscal 2019.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2019 was $11.15M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2018 was -$1.39M, a 715.04% decline from fiscal 2017.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2017 was $226.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2020-12-31 | $6.42M 10-K/A · filed 2021-04-09 | |||
| 2019-12-31 | $11.15M 10-K/A · filed 2021-04-09 | |||
| 2018-12-31 | -$2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$2.21M derived: sum of 2 quarters · filed 2020-03-16 | -$1.51M derived: sum of 3 quarters · filed 2020-03-16 | -$1.39M 10-K · filed 2020-03-16 |
| 2018-09-30 | $565.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.27M derived: sum of 2 quarters · filed 2018-11-09 | $1.39M 10-Q · filed 2018-11-09 | $1.38M derived: sum of 4 quarters · filed 2019-03-18 |
| 2018-06-30 | $707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $825.00K 10-Q · filed 2018-08-09 | $810.00K derived: sum of 3 quarters · filed 2019-03-18 | $1.56M derived: sum of 4 quarters · filed 2019-03-18 |
| 2018-03-31 | $118.00K 10-Q · filed 2018-05-10 | $103.00K derived: sum of 2 quarters · filed 2019-03-18 | $855.00K derived: sum of 3 quarters · filed 2019-03-18 | $1.01M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $737.00K derived: sum of 2 quarters · filed 2019-03-18 | $894.00K derived: sum of 3 quarters · filed 2019-03-18 | $226.00K 10-K · filed 2019-03-18 |
| 2017-09-30 | $752.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $909.00K derived: sum of 2 quarters · filed 2017-11-09 | $241.00K 10-Q · filed 2017-11-09 | $970.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | $157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$511.00K 10-Q · filed 2017-08-09 | $218.00K derived: sum of 3 quarters · filed 2018-03-16 | $137.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | -$668.00K 10-Q · filed 2017-05-10 | $61.00K derived: sum of 2 quarters · filed 2018-03-16 | -$20.00K derived: sum of 3 quarters · filed 2018-03-16 | -$821.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | $729.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $648.00K derived: sum of 2 quarters · filed 2018-03-16 | -$153.00K derived: sum of 3 quarters · filed 2018-03-16 | -$1.07M 10-K · filed 2018-03-16 |
| 2016-09-30 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$882.00K derived: sum of 2 quarters · filed 2016-11-09 | -$1.80M 10-Q · filed 2016-11-09 | -$3.41M derived: sum of 4 quarters · filed 2017-03-16 |
| 2016-06-30 | -$801.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$1.72M 10-Q · filed 2016-08-09 | -$3.33M derived: sum of 3 quarters · filed 2017-03-16 | -$4.80M derived: sum of 4 quarters · filed 2017-03-16 |
| 2016-03-31 | -$918.00K 10-Q · filed 2016-05-10 | -$2.53M derived: sum of 2 quarters · filed 2017-03-16 | -$4.00M derived: sum of 3 quarters · filed 2017-03-16 | -$2.38M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$3.08M derived: sum of 2 quarters · filed 2017-03-16 | -$1.46M derived: sum of 3 quarters · filed 2017-03-16 | -$1.68M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $150.00K derived: sum of 2 quarters · filed 2016-11-09 | -$65.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $1.41M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$215.00K 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $942.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |